272 related articles for article (PubMed ID: 17828616)
1. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Yang T; Choi MK; Cui FD; Lee SJ; Chung SJ; Shim CK; Kim DD
Pharm Res; 2007 Dec; 24(12):2402-11. PubMed ID: 17828616
[TBL] [Abstract][Full Text] [Related]
2. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
Yang T; Choi MK; Cui FD; Kim JS; Chung SJ; Shim CK; Kim DD
J Control Release; 2007 Jul; 120(3):169-77. PubMed ID: 17586082
[TBL] [Abstract][Full Text] [Related]
3. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization,
Raikwar S; Yadav V; Jain S; Jain SK
J Liposome Res; 2024 Jun; 34(2):239-263. PubMed ID: 37594466
[TBL] [Abstract][Full Text] [Related]
4. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
Yang T; Cui FD; Choi MK; Cho JW; Chung SJ; Shim CK; Kim DD
Int J Pharm; 2007 Jun; 338(1-2):317-26. PubMed ID: 17368984
[TBL] [Abstract][Full Text] [Related]
5. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
6. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
7. Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Narayanaswamy R; Torchilin VP
Pharm Res; 2021 Mar; 38(3):429-450. PubMed ID: 33655395
[TBL] [Abstract][Full Text] [Related]
8. Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer.
Peng J; Chen J; Xie F; Bao W; Xu H; Wang H; Xu Y; Du Z
Biomaterials; 2019 Nov; 222():119420. PubMed ID: 31445322
[TBL] [Abstract][Full Text] [Related]
9. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
[TBL] [Abstract][Full Text] [Related]
13. Targeted prodrug treatment of HER-2-positive breast tumor cells using trastuzumab and paclitaxel linked by A-Z-CINN Linker.
Gilbert CW; McGowan EB; Seery GB; Black KS; Pegram MD
J Exp Ther Oncol; 2003; 3(1):27-35. PubMed ID: 12724856
[TBL] [Abstract][Full Text] [Related]
14. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
[TBL] [Abstract][Full Text] [Related]
16. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles.
Debotton N; Parnes M; Kadouche J; Benita S
J Control Release; 2008 May; 127(3):219-30. PubMed ID: 18343522
[TBL] [Abstract][Full Text] [Related]
17. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
Razumienko E; Dryden L; Scollard D; Reilly RM
Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer.
Chen Y; Wang L; Luo S; Hu J; Huang X; Li PW; Zhang Y; Wu C; Tian BL
Drug Des Devel Ther; 2020; 14():2945-2957. PubMed ID: 32801636
[TBL] [Abstract][Full Text] [Related]
20. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
